88 results about "Hypolipidemic Drugs" patented technology

The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.

The invention relates to a statins antilipemic drugs furazan nitroxides derivates and a preparation method thereof, and solves the problems of nonlipid-lowering and low activity in statins antilipemic drugs and adverse effect. The invention is shown as formula (1).

The invention provides a polygonatum canaliculatum polysaccharide and a preparation method thereof. The polygonatum canaliculatum polysaccharide is extracted from the perennial liliaceae herbal plant of polygonatum canaliculatum and has the molecular weight of 5,000 to 100,000 Daltons. The solid polygonatum canaliculatum polysaccharide is off white or white. The monosaccharide consists of pyrane type beta-D-galactose, D-glucose and D-mannose. The product can be developed into medicines capable of reducing blood sugar and blood fat. The preparation method is reliable and feasible, and is suitable for the volume product without environmental pollution. The preparation method has low cost.

The invention relates to the use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat with the general formula (I), wherein R, R1, R2 are defined in the specification, the piperamide compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, such as atherosclerotic, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The invention discloses a modified spectrophotometry for detecting activity of HMG-CoA reducase and applications thereof. The detecting method comprises the following steps: a. preparing liver microsome by centrifuging fresh liver organics; b. carrying out weight drop, homogenate, dilution and centrifugation on the liver microsome, then obtaining a supernatant, and obtaining the reducase source containing dissolvable HMG-CoA; c. detecting the protein content of HMG-CoA reducase source, and diluting the HMG-CoA reducase source to have the known concentration; and d. adding the HMG-CoA reducase source to the optimized reaction system, and detecting the OD340 value and calculating the enzyme activity. The detecting system for HMG-CoA reducase inhibitor is established on the basis of the detecting method and is used for calculating the enzyme activity inhibition rate and half-inhibition concentration (IC50), and can be used for screening hypolipidemic drugs. The modified spectrophotometry has the advantages of system optimization, high safety, low price, batch filtration, credible conclusion and the like, can effectively screen the HMG-CoA reducase activity inhibitor, and provides a simple and quick method for developing the hypolipidemic drugs.

The invention relates to a use of total flavonoids from radix Daphne genkwa plants in preparing weight-losing hypolipemic drugs, especially weight losing, which achieves the purpose of losing weight and simultaneously can lower the content of TC, TG and LDL-C and raise the content of HDL-C.

The purpose in this invention is to providing drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia that is much frequency among the duplication onset in geriatric diseases. This invention is related to drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia of which active principles are 2-propyl-3- {[2'-(1H-tetrazole -5-yl) biphenyl -4-yl]methyl}-5, 6, 7, 8-tetrahydrocyclohepta imidazole -4-(3H) - one and that prodrug or that salt. Pratosartan is able to use in combination with one or more than two diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan is able to use in combination with one or more than two hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.

The invention provides a hypolipidemic compound 9-demethylberberine. The 9-demethylberberine is derived from a main in-vivo metabolite of natural medicine berberine, and is also named as berberrubine. The researches on model animals with hyperlipidemia find that the 9-demethylberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

The invention discloses a preparation method of a hypolipidemic compound Fuzhuan tea element A and application of the compound in reducing the blood fat. Aspergillus niger is inoculated to ferment tealeaves, and the Fuzhuan tea element A is purified and prepared by virtue of technologies such as column chromatography, extraction and the like. The method comprises the following steps: (1) fermenting; (2) crushing tealeaves; (3) extracting by utilizing a methanol solvent with the volume concentration of 80 percent; (4) concentrating filtrate; (5) separating and purifying by virtue of column chromatography: selecting 7cm, 5.5cm and 3cm chromatographic columns to be filled with silica gel and sephadex gel, and separating; (6) adding acetonitrile to extract; (7) freeze drying: freezing the collected supernatant in a refrigerator, and freeze drying by utilizing a freeze drying machine. The compound Fuzhuan tea element A is high in purity and can be used for preparing a hypolipidemic drug.

The invention relates to a hypolipidemic drug combination formed by combining polyunsaturated fatty acid with plant polyphenol, in particular to hypolipidemic drug using EPA and EGCG or resveratrol as main active ingredients. Experimental studies show that the combination can remarkably lower blood lipid level and improve hemorheology and has remarkable effect on regulating blood lipid and preventing and treating diseases related to blood lipid metabolism abnormality. The combination is extensive in raw material source, low in cost and worthy of popularization and application.

The present invention discloses a lipid nanoparticle comprising a lipopeptide molecule, dioleoyl phosphoethanolamine, cholesterol, and polyethylene glycol, and the lipid nanoparticle encapsulates Cas9mRNA and a sgRNA molecule in a gene conserved region of target mouse and human Proprotein Convertase subtilisin / kexin type 9 ( PCSK9). The present invention also discloses a preparation method and use of the lipid nanoparticle, and a pharmaceutical composition and formulation comprising the lipid nanoparticle. The lipid nanoparticle and the biological preparation can be used as a novel delivery system for a PCSK9 inhibitor hypolipidemic drug.

The invention provides a hypolipidemic compound demethyleneberberine. The demethyleneberberine is derived from a main in-vivo metabolite of natural medicine berberine. The researches on model animals with hyperlipidemia find that the demethyleneberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

The invention provides a composition for supplementing all nutrients and a preparation method of the composition for supplementing all nutrients, and relates to the field of special foods. The composition for supplementing all nutrients comprises the components of protein, fat, carbohydrate, dietary fibers, vitamins and minerals, can supplement various nutrients required by human bodies, can meetrequirements of growth and development and metabolism of human bodies, and besides, also has the effects of reinforcing the immunity of organisms and pharmacological activity of medicines for reducingblood lipid. In addition, the proportion of vitamin C to myo-inositol is adjusted, so that the pharmacological action of the medicines for reducing blood lipid is notably improved.

The invention relates to a use of yuenkanin organic acid extracted from yuenkanin plants for preparing weight-losing and blood lipid-lowering medicine, particularly losing weight, and simultaneously, the contents of TC, TG and LDL-C in blood serum can be further reduced and the content of HDL-C level is increased.

The invention discloses lipid-decreasing pentapeptide derived from Miichthysmiiuy swimming bladders. The amino acid sequence of the lipid-decreasing pentapeptide is Gly-Ile-Glu-Trp-Ala(GIEWA), and themolecular weight determined by virtue of ESI-MS is 574.64Da. The lipid-decreasing pentapeptide is prepared by the steps of processing the Miichthysmiiuy swimming bladders by virtue of alkali leachingand alcohol degreasing so as to obtain degreased Miichthysmiiuy swimming bladders, carrying out enzymolysis by virtue of alkaline protease, and carrying out ultrafiltration, ion exchange resin chromatography, gel column chromatography and reversed-phase high performance liquid chromatography purification on enzymatic hydrolysate, so as to obtain the lipid-decreasing pentapeptide derived from theMiichthysmiiuy swimming bladders. The invention simultaneously discloses application of the lipid-decreasing pentapeptide derived from the Miichthysmiiuy swimming bladders in lipid-decreasing active components, health products and food additives. According to the lipid-decreasing pentapeptide derived from the Miichthysmiiuy swimming bladders, adipogenesis genes can be reduced, the oxidation of fatty acid beta can be promoted, the generation of lipids can be promoted, and the pentapeptide has good lipid-decreasing activity, and can be developed into lipid-decreasing drugs, health products and food additives.

The invention relates to a choline salt of a hypolipidemic drug and a preparation method and a pharmaceutical use thereof. The invention provides a choline salt of a class of hypolipidemic drugs, and the hypolipidemic drugs include but not limited to clofibrate, libet, fenofibrate, ciprofibrate, gemfibrozil, acipimox, niacin, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, pitavastatin, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and other unsaturated fatty acids. The choline salt of the hypolipidemic drug can be used for treating hyperlipidemia and other cardiovascular diseases. The invention also provides a preparation method of the choline salt of the hypolipidemic drug.

The invention relates to the field of medicines, in particular to an application of blautia producta to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia, and provides an application of preparations for increasing bacterium level, uniformity or proportion of blautia producta (Blautia) to preparation of products for strengthening treatment efficacy of blood lipid reducing drugs on hyperlipemia, and a medical composition and an application of the medical composition to preparation of products for treating hyperlipaemia. The preparations for increasing the bacterium level, uniformity or proportion of blautia producta (Blautia) in intestinal flora of an examinee, the level, the uniformity or the proportion of beneficial microorganisms inthe examinee can be increased, and further the responsiveness of the examinee on a blood lipid reducing treatment method is strengthened, so that the lipid reducing efficacy of the blood lipid reducing drugs can be notably improved, and the individual difference is reduced.

The invention discloses a traditional Chinese medicine composition containing glossy ganoderma. The composition comprises the following components in parts by weight: 1-25 parts of sea-buckthorn, 3-30 parts of salvia miltiorrhiza and 1-3 parts of glossy ganoderma. The invention also discloses a preparation method of the traditional Chinese medicine composition. The preparation method comprises the steps of extracting active ingredients and preparing the finished product according to the formula. The traditional Chinese medicine composition makes the best of the treatment effects of active pharmaceutical ingredients on cardiovascular diseases, adopts scientific matching, generates synergistic effects, has better curative effects and more controllable quality than traditional blood lipid reducing medicine preparations and is suitable for industrial production.

The present invention relates to the technical field of food and / or pharmaceuticals, and discloses a blood fat lowering composition and a preparation method and application thereof. The blood fat lowering composition comprises Echium vulgare seed oil, camelina seed oil and safflower seed oil. The blood fat lowering composition is a natural composition which comprises specific natural substances the Echium vulgare seed oil, the camelina seed oil and the safflower seed oil as active ingredients, and can significantly reduce total cholesterol and triglyceride and increase serum apolipoprotein A1content. The blood fat lowering composition has an obvious hypolipidemic effect and can be applied to the development and preparation of hypolipidemic drugs and foods, especially health foods.

The invention relates to the technical field of traditional Chinese medicine, in particular to a blood lipid-lowering agent, which is made of the following raw materials in parts by mass: 22-28 parts of Salvia miltiorrhiza, 22-28 parts of Polygala, 18-28 parts of Snake Grape, 18- 28 servings, 18-28 servings of hanging golden lanterns, 16-24 servings of Puhuang, 16-24 servings of radish seeds, 14-20 servings of cinnamon, 14-20 servings of Ligustrum lucidum, 10-20 servings of intermittent, 5-15 servings of Polygonum cuspidatum 5-15 parts of dandelion, 5-15 parts of scallion, 5-15 parts of elm money, 5-15 parts of garcinia cambogia, 5-7 parts of kudzu root, 5-7 parts of scutellaria chinensis, 3-5 parts of fennel. The blood lipid-lowering agent of the present invention can promote the transformation of cholesterol, promote the expression of LDL receptors on cell membranes, accelerate the decomposition of lipoproteins; activate lipoprotein metabolic enzymes, promote the hydrolysis of triglycerides; and promote the metabolism of other lipids ; It can effectively remove the cholesterol deposited on blood vessels, prevent platelet aggregation, and reduce the occurrence of heart disease.

The invention relates to an auricularia auricula hypolipidemic active part and a preparation method and application thereof. The active part, with an in-vitro inhibition effect on lipase, of auricularia auricula is obtained through a preparation method. Animal experiments show that the active part has a hypolipidemic effect; it is tested that the active part comprises 15.6-35.9% of triterpenoid components and 28.4-53.6% of polyphenol components, and the activity is high when the mass ratio of the triterpenoid components to the polyphenol components is 1:(2.2-2.9). The active part of the auricularia auricular can be used for preparing hypolipidemic drugs, and has good development and application prospects. The invention further discloses a main ingredient range of the auricularia auricula hypolipidemic active part. Quality standard improvement and control are facilitated during later development and application.

The invention discloses an application of dehydrodeacetoxychamomile or deacetylchamomile ketone in preparation of hypoglycemic and hypolipidemic drugs. Blood sugar and blood fat serve as two importantindexes reflecting the health level of the human body and have important reference significance in disease treatment and health care. Therefore, keeping blood sugar and blood fat indexes stable becomes an important research direction for treating related diseases. It is found that the dehydrodeacetoxychamomile and the deacetylchamomile ketone have excellent alpha-glucosidase inhibitory activity and pancreatic lipase inhibitory activity, and therefore the dehydrodeacetoxychamomile and the deacetylchamomile ketone have the prospect of being developed into the hypoglycemic and lipid-lowering medicine.

The invention discloses a preparation method of a hydrophobically modified poly-cation chelating agent. The preparation method comprises the following steps (1) dissolving allylamine and sodium carbonate in an organic solvent, dripping bromo-hydrocarbon, and filtering, washing and concentrating to obtain N-alkyl allylamine after reaction; (2) dripping hydrochloric acid into N-alkyl allylamine to be neutral, and collecting and drying precipitate to obtain N-alkyl allylamine hydrochloride; (3) dissolving N-alkyl allylamine hydrochloride and dimethyl diallyl ammonium chloride in water, adding an initiator into the mixture, performing polymerization reaction, dripping absolute ethyl alcohol to the reaction product, and collecting precipitate to produce the hydrophobically modified poly-cation chelating agent. The fatty alkyl chain is introduced into the side chain of macromolecule, so that compared with the commercially available hydrophobically modified poly-cation chelating agent as a cholic acid chelating agent, the toxic and side effects of the hydrophobically modified poly-cation chelating agent are obviously reduced due to hydrophobic association action; the hydrophobically modified poly-cation chelating agent has wide application prospect in the development field of new hypolipidemic drugs.

The invention belongs to the technical field of medicines, and particularly provides a methylpyrazine derivative-piperazine eutectic crystal, a preparation method thereof and application of the eutectic crystal in preparation of hypolipidemic drugs. The methylpyrazine derivative-piperazine eutectic crystal is radiated by Cu-Kalpha, and an X-ray diffraction pattern expressed by 2theta has characteristic peaks at 8.8 + / -0.2 degrees, 13.0 + / -0.2 degrees, 14.7 + / -0.2 degrees, 25.2 + / -0.2 degrees, 27.2 + / -0.2 degrees and 28.9 + / -0.2 degrees. After the methylpyrazine derivative-piperazine eutectic crystal prepared by the method is placed in a solid state, the product is high in purity and good in stability, and animal experiments prove that the bioavailability is high. The eutectic crystal is simple in preparation process and has a good industrial application prospect.

The invention discloses an active targeting blood fat lowering drug with nanocarbon crystals as a carrier and belongs to the field of cardiovascular drugs. The nanocarbon crystals serve as the carrier, and galactosamine and statin drugs are supported on the carrier. The invention further discloses a preparation method of the active targeting blood fat lowering drug. The preparation method includes the steps that galactosamine is supported on the nanocarbon crystals, and the statin drugs are supported on the nanocarbon crystals supported with galactosamine. According to the active targeting blood fat lowering drug with the nanocarbon crystals as the carrier, the nanocarbon crystals serve as the carrier, one kind of the statin drugs can be carried, the active targeting blood fat lowering drug can reach a focus in an active targeting mode under the effect of hepatic cell active targeting factor galactosamine, and finally achieves the effect of lowering blood fat and eliminating arteriosclerosis.

The invention relates to an application of transformed type ginsenosides or pharmaceutically acceptable sodium, ester, and solvate in preparation of hypolipidemic drugs. The transformed type ginsenosides are found for the first time to have effect of lowering blood fat, and can reduce contents of TC and non-HDL-C in the blood, and reduce ratio of the contents of the non-HDL-C and the HDL-C; also can suppress formation of foam cells to reduce area of atherosclerotic plaque on the inner walls of aorta, can help to develop a new hypolipidemic drug suitable for patients with abnormal blood lipids,and provides theoretical and technical guidance for prevention and control of the vascular diseases.

The invention provides a eucheuma blood fat reducing tetrapeptide and an application thereof, and belongs to the technical field of blood pressure reducing oligopeptide. The amino acid sequence of theeucheuma blood fat reducing tetrapeptide is Phe-Tyr-Lys-Ala (FYKA), and the eucheuma blood fat reducing tetrapeptide has good fat reducing activity. The eucheuma blood fat reducing tetrapeptide can be applied to preparation of blood fat reducing drugs, health care products and food additives. The eucheuma blood fat reducing tetrapeptide can remarkably reduce fat accumulation amount of oleic acidinduced hepatic cells, remarkably reduces the level of triglyceride (TG) and total cholesterol (TC) in the hepatic cells, has good blood fat reducing activity and can be used for developing the bloodfat reducing related drugs, the health care products and special medical food.

The invention belongs to the technical field of health food, and particularly relates to a traditional Chinese medicine composition with an auxiliary blood fat reduction function and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises 20-50 parts of cyclocarya paliurus leaf, 25-55 parts of ampelopsis grossedentata leaf, 25-55parts of lophatherum gracile, 30-60 parts of green plum, 55-85 parts of hawthorn, 85-115 parts of pine pollen and 90-120 parts of radix puerariae. The traditional Chinese medicine composition can beadministrated independently as routine health food by a hyperlipidemia patient or matched with statin hypolipidemic drugs for use; the preparation method of the traditional Chinese medicine composition is stable, operable and suitable for industrial production; and the prepared composition is good in safety and has an obvious blood fat reduction effect.

The invention discloses blood-lipid-reducing black sesame seed oil and a preparation method thereof. The blood-lipid-reducing black sesame seed oil is prepared from black sesame seeds, linseed oil, grape seed oil, rhizoma curcumae longae, cassia seeds, Chinese thorowax roots, hawthorn fruits, Chinese wolfberry fruits and green tea powder. The black sesame seed oil prepared by the preparation method is rich in nutrients and good in taste; and the black sesame seed oil has the functions of lowering blood pressure, reducing blood lipid, reducing and regulating blood glucose, and enhancing human body immunity. Being frequently taken, the black sesame seed oil is especially capable of effectively controlling blood lipid of patients with hyperlipidemia so as to reduce dosage of hypolipidemic drugs.